The invention relates to 18-20 member bi-polycyclic compounds, methods of making these compounds, and methods of using them in treating hyperproliferative disorders (e.g., cancer) and non-malignant tumors promoting muscle formation inhibiting muscle degeneration or the loss of muscle mass or muscle function and myofibers ex vivo.